Sorrento Announces the Publication of Data published in Cell Press Journal Med Describing the Preclinical and Discovery Efficacy and Discovery of a broad-acting SARS-CoV-2 neutralizing Antibody administered by IV (STI-9167) OR IN (STI-9199) (STI-9199) Yahoo Finance

SAN DIEGO San Diego, October. 14th 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq:”SRNE, “Sorrento”) has today announced the publication within the Cell Press journal Med of research findings that relates to the discovery as well as preclinical testing of STI-9167’s neutralizing antibody’s activity against the broad range of variants of SARS-CoV-2, including specific Omicron subvariants. The protection against Omicron-related diseases in the vivo as a preliminary test model was demonstrated following the administration of STI-9167 via an intravenous (IV) route or after administration via using the IN (IN) route, using an intranasal version of the antibody, dubbed”STI-9199.

The publication’s link can be found here:

https://www.cell.com/med/fulltext/S2666-6340(22)00321-X

More About Sorrento Therapeutics, Inc.

Sorrento is a commercial and clinical stage biopharmaceutical firm that is developing novel therapies for treating cancer, pain (non-opioid treatments) as well as autoimmune diseases, and COVID-19. Sorrento’s multimodal and multi-pronged strategy to fight cancer is possible because of its vast immuno-oncology platform, which include key assets such as new-generation tyrosine-kinase inhibitors (“TKIs”) and fully human-derived antigens (“G-MAB(tm) library”) as well as immuno-cellular treatments (“DAR-T(tm )”), antibody-drug conjugates (“ADCs”) along with oncolytic virus (“Seprehvec(tm )”). Sorrento is also working on potential antiviral treatments and vaccines for coronaviruses, such as STI-1558 COVISHIELD(tm) as well as COVIDROPS(tm) and diagnostic test solutions, such as COVIMARK(tm).

Sorrento’s dedication to life-enhancing treatments for patients is also evident by our efforts to develop the development of a (TRPV1 antagonist) non-opioid pain-management small molecule called resiniferatoxin (“RTX”) as well as SP-102 (10 mg dexamethasone sodium-phosphate viscous gel) (SEMDEXA(tm)), an innovative, viscous gel-based formulation for a commonly prescribed corticosteroid for the treatment of lumbosacral radicular pain or sciatica and commercializing ZTlido(r) (lidocaine the topical treatment) 1.8 percent to treat Pneumo-Neuralgia (PHN). RTX is approved to be used in an Phase II clinical trial to treat chronic pain caused by cancer and also a Phase II trial for osteoarthritis patients. The positive final results of the phase III Pivotal Trial C.L.E.A.R. Programme for SEMDEXA(tm) its new non-opioid medication for treating the lumbosacral pain of the radicular region (sciatica) and were released in March 2022. ZTlido(r) received approval from the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

forward-looking statements

This press release as well as any statements made during any conference or presentation include forward-looking information about Sorrento Therapeutics, Inc. in accordance with the safe protection clauses of Section 21E under the Private Securities Litigation Reform Act of 1995, and are subject to the risks and uncertainties that could cause the actual results to differ significantly from the ones projected. These statements are based on the expectations of Sorrento’s its subsidiaries’ technologies as well as products that are candidates for development. The risks as well as uncertainties which could make our actual results be different and adversely different from those described in our forward-looking statements include, but aren’t only limited to risks related to Sorrento’s subsidiary and affiliates’ partners’ technology and prospects and collaborations with partners clinical development risks, which include risks related to the progress in the timing, cost and outcomes of clinical trials and development plans; risks of delays or difficulties in getting regulatory approvals; and the risk that the results of clinical studies could not meet any or all of the objectives of a clinical trial and that the data derived from these studies could not be sufficient to support a submission or approval; risk that previous study, test or trial results will never be reproduced for subsequent or further studies or trials as well as the risks associated with producing and supplying drug products as well as the risks of using the knowledge of its employees as well as affiliates, subsidiaries, and partners to support Sorrento in the implementation of its candidates’ strategies; risks relating to COVID-19’s global impact and other risks detailed in the most current periodic reports to the Securities and Exchange Commission, including Sorrento’s Annual report in Form 10-K of the fiscal year that ended on Dec 31, 2021, and the subsequent Quarterly Reports on Form 10-Q that are filed in the Securities and Exchange Commission, including the risks and uncertainties outlined in the filings. It is advised not to make any reliance on these forward-looking statements that reflect only today’s date for this press release and we do not assume any obligation to revise any forward-looking information contained that appears in this release, except when required by the law.

Media and Investor Relations

Contact Information: Brian Cooley

Email: [email protected]

Sorrento(r) and Sorrento(r) and the Sorrento logos are trademarks registered with the Sorrento Therapeutics, Inc. owned by Sorrento Therapeutics, Inc.

G-MAB(tm), DAR-T(tm), Seprehvec(tm), SOFUSA(tm), COVISHIELD(tm), COVIDROPS(tm), COVI-MSC(tm), COVIMARK(tm) and Fujovee(tm) are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA(tm) (SP-102) SEMDEXA(tm) (SP-102) trademark of Semnur Pharmaceuticals, Inc. A review of the name’s proprietary from the FDA is in the works.

ZTlido(r) is a trademark registered by Scilex Pharmaceuticals Inc.

All other trademarks are rightful property of their respective owners.

(c)2022 Sorrento Therapeutics, Inc. All Rights Reserved.